Heritage Investors Management Corp Sells 1,529 Shares of Thermo Fisher Scientific Inc. $TMO

Heritage Investors Management Corp lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,918 shares of the medical research company’s stock after selling 1,529 shares during the quarter. Thermo Fisher Scientific makes up 1.1% of Heritage Investors Management Corp’s investment portfolio, making the stock its 26th largest holding. Heritage Investors Management Corp’s holdings in Thermo Fisher Scientific were worth $38,423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Bank OZK acquired a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $1,096,000. Ausdal Financial Partners Inc. purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $456,000. BlackRock Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $15,501,867,000. German American Bancorp Inc. purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $4,920,000. Finally, Parallax Volatility Advisers L.P. purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $814,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TMO shares. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. BMO Capital Markets downgraded shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. UBS Group reiterated a “buy” rating and set a $800.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, October 22nd. Stifel Nicolaus lifted their price objective on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Finally, Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $689.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 76,199 shares of company stock worth $45,896,780 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $696.78 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a market cap of $257.63 billion, a PE ratio of 36.75, a PEG ratio of 2.84 and a beta of 0.84. The firm’s 50 day moving average price is $654.87 and its 200 day moving average price is $552.94. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The company had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the previous year, the firm posted $5.79 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.